Adult Brain Tumor Consortium
Welcome,         Profile    Billing    Logout  
 20 Trials 
32 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cloughesy, Timothy F
NCI-2018-02010, NCT03732352: 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

Completed
2
12
US
Fludeoxyglucose F-18, 18FDG, FDG, fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Osimertinib, AZD-9291, AZD9291, Mereletinib, Tagrisso, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging
Jonsson Comprehensive Cancer Center, AstraZeneca
EGFR Gene Amplification, EGFR Gene Mutation, Glioblastoma, Recurrent Glioblastoma, Supratentorial Glioblastoma, TP53 Wt Allele
01/24
01/24
NCT03382977: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Recruiting
1/2
98
US
VBI-1901, Carmustine, BiCNU, Lomustine, Gleostine
VBI Vaccines Inc.
Glioblastoma Multiforme
07/25
08/25
NCT05664243: A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

Active, not recruiting
1/2
4
US
Autologous genetically modified gamma-delta T cells, Allogeneic genetically modified gamma-delta T cells
In8bio Inc.
Glioblastoma
12/25
12/25
NCT02101905: Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

Completed
1
29
US
Laboratory Biomarker Analysis, Lapatinib, GSK572016, GW 2016, GW 572016, GW-572016, GW2016, GW572016, Lapatinib Ditosylate, Tykerb, Pharmacological Study, Therapeutic Conventional Surgery
National Cancer Institute (NCI)
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Gliosarcoma, Mixed Glioma, Recurrent Adult Brain Neoplasm, Recurrent Glioblastoma
10/21
10/24
NCT04201873: Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

Recruiting
1
40
US
Dendritic Cell Tumor Cell Lysate Vaccine, DC tumor cell lysate vaccine, dendritic cell-pulsed tumor cell lysate vaccine, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Placebo Administration, Poly ICLC, Hiltonol, Poly I:Poly C with Poly-L-Lysine Stabilizer, poly-ICLC, PolyI:PolyC with Poly-L-Lysine Stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose, Stabilized Polyriboinosinic/Polyribocytidylic Acid
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI), Merck Sharp & Dohme LLC, Phase One Foundation, Oncovir, Inc.
Recurrent Glioblastoma
08/25
08/26
Nabors, Louis B
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT02093624: A Phase II Trial of Rituximab In Myasthenia Gravis

Not yet recruiting
2
50
US
Rituximab, Placebo
Yale University
Myasthenia Gravis
05/17
12/17
ExTINGUSH, NCT04372615: The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

Recruiting
2
116
Europe, US
Inebilizumab, UPLIZNA, Placebo
University of Utah
Autoimmune Encephalitis, Encephalitis
10/25
08/26
NCT05664243: A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

Active, not recruiting
1/2
4
US
Autologous genetically modified gamma-delta T cells, Allogeneic genetically modified gamma-delta T cells
In8bio Inc.
Glioblastoma
12/25
12/25
UAB 1773, NCT04165941: Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma

Active, not recruiting
1
21
US
DRI cell therapy
University of Alabama at Birmingham, In8bio Inc.
Brain Tumor Adult
12/24
12/24
NCT05879367: Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma

Recruiting
1
66
US
Eflornithine (Dose Level 1), DFMO, Eflornithine (Dose Level 2), Eflornithine (Dose Level -1), Temozolomide, Temodar, TMZ
Orbus Therapeutics, Inc.
Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM
12/24
12/24
NCT04566393: Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies

Available
N/A
US
Ulixertinib (BVD-523)
xCures, Cancer Commons
Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma, Non Small Cell Lung Cancer, Thyroid Cancer, Bladder Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer, Cholangiocarcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Glioblastoma, MAPK Gene Mutation, KRAS Activating Mutation, BRAF Gene Mutation, NRAS Gene Mutation, HRAS Gene Mutation, MEK Mutation, ERK Mutation
 
 
Groot, John de
LIBERATE, NCT05383872: Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors

Recruiting
N/A
57
Canada, US
Focused Ultrasound (Exablate Model 4000)
InSightec
Glioblastoma, Glioma, Liquid Biopsy
12/24
03/25
Fiveash, John
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

Active, not recruiting
3
270
Europe, Canada, US, RoW
NovoTTF-200M device, Best Standard of Care
NovoCure GmbH
Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
12/24
12/24
NCT04114981: Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease

Active, not recruiting
3
242
Canada, US
Single Fraction Stereotactic Radiosurgery, Stereotactic Radiosurgery, Fractionated Stereotactic Radiosurgery, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Brain
03/25
03/28
NCT00887146 / 2008-007295-14: Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

Active, not recruiting
3
305
Europe, Canada, US
concomitant temozolomide (TMZ), radiotherapy, procarbazine, adjuvant temozolomide (TMZ), CCNU, vincristine
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), European Organisation for Research and Treatment Center (EORTC), Canadian Cancer Trials Group
Brain and Central Nervous System Tumors
10/25
10/25
NRG-BN005, NCT03180502: Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma

Active, not recruiting
2
148
US
IMRT (Intensity-Modulated Radiation Therapy), IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Proton Beam Radiation Therapy, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac
NRG Oncology, National Cancer Institute (NCI)
1p/19q Co-deletion, Anaplastic Astrocytoma, Diffuse Astrocytoma, Glioma, IDH1 Gene Mutation, IDH2 Gene Mutation, Oligoastrocytoma, Oligodendroglioma, WHO Grade III Glioma
06/26
01/30
RAD1705, NCT03412812: A Dose Escalation Trial of Five Fraction Stereotactic Radiation Therapy for Brain Metastases

Active, not recruiting
N/A
13
US
Dose Escalated Five Fraction Stereotactic Radiosurgery
University of Alabama at Birmingham
Brain Metastases
01/24
02/25
NCT02708810: RAD 1501: A Trial of Virtual Cone Trigeminal Neuralgia Radiosurgery

Active, not recruiting
N/A
40
US
Unframed Virtual Cone, Face Mask, 80 Gy Radiation, Radiosurgery
University of Alabama at Birmingham
Trigeminal Neuralgia
10/25
10/25
NCT03305588: RAD 1601: EDGE Radiosurgery for Intractable Essential Tremor and Tremor-Dominant Parkinson's Disease

Active, not recruiting
N/A
40
US
Unframed Virtual Cone
University of Alabama at Birmingham
Essential Tremor, Parkinson Disease
12/25
12/25
NCT05270707: HyperArc Registry Study

Recruiting
N/A
5000
US, RoW
Stereotactic radiosurgery, HyperArc SRS
Varian, a Siemens Healthineers Company
Brain Metastases, CNS Neoplasm, CNS Disorder, Intracranial
12/31
12/31
Ahluwalia, Manmeet
NCT05317858: Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

Recruiting
3
20
Canada, US, RoW
Blood Brain Barrier Disruption - Oncology, Exablate BBBD, Pembrolizumab
InSightec
Brain Tumor
06/24
12/24
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

Active, not recruiting
3
270
Europe, Canada, US, RoW
NovoTTF-200M device, Best Standard of Care
NovoCure GmbH
Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
12/24
12/24
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().

Recruiting
3
600
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen Inc.
Carcinoma, Non-Small-Cell Lung
07/26
07/28
SURVIVE, NCT05163080: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Active, not recruiting
2
247
US
SurVaxM
MimiVax, LLC, Translational Drug Development, Merit
Newly Diagnosed Glioblastoma
08/24
08/24
NCT05188508: Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

Recruiting
2
57
US
Pembrolizumab, Olaparib and Temozolomide
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC
Glioma
01/25
01/25
NCT02575794: Terameprocol in Treating Patients With Recurrent High Grade Glioma

Completed
1
20
US
Terameprocol, 1,1'-(2,3-Dimethyl-1,4-butanediyl)bis(3,4-dimethoxybenzene), EM-1421, M4N, tetra-O-methyl NDGA, Tetra-O-methyl Nordihydroguaiaretic Acid, TMNDGA, Pharmacological Study, Pharnacological Study
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Erimos Pharmaceuticals, National Cancer Institute (NCI)
High Grade Glioma (III or IV)
09/23
10/23
NCT04901806: Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

Terminated
1
29
Europe, US, RoW
PBI-200
Pyramid Biosciences
Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor
07/23
07/23
TUTOR, NCT05553522: Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer

Recruiting
1
40
US
Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine
Baptist Health South Florida, Seagen Inc.
Brain Metastases, HER2-positive Breast Cancer
11/24
11/25
CAMPERR, NCT05366881: cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

Recruiting
N/A
7000
US
Adela, Inc
Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Stomach Cancer, Head and Neck Cancer, Hepatobiliary Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cancer, Sarcoma, Thyroid Cancer
09/25
12/26
LIBERATE, NCT05383872: Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors

Recruiting
N/A
57
Canada, US
Focused Ultrasound (Exablate Model 4000)
InSightec
Glioblastoma, Glioma, Liquid Biopsy
12/24
03/25
NCT05756985: Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue

Not yet recruiting
N/A
120
US
Specimen Collection
Baptist Health South Florida, Miami Cancer Institute, Nico Corporation
Glioblastoma, Glioblastoma Multiforme, Gliosarcoma
09/26
09/28
Alexander, Brian
No trials found

Download Options